Can extended‑release Ativan (lorazepam) be used instead of diazepam for rapid seizure control?

There is no extended-release formulation of Ativan (lorazepam) available for seizure control

Lorazepam only exists in immediate-release formulations (IV, IM, oral, sublingual), and there is no extended-release version that can be used for rapid seizure control. The question appears to be based on a misunderstanding about available formulations.

Why This Matters for Seizure Management

Pharmacokinetic Considerations

The choice between lorazepam and diazepam for status epilepticus is based on their immediate-acting properties, not extended-release characteristics:

• Lorazepam has a longer duration of anticonvulsant activity (12-24 hours) due to slower redistribution from the CNS, despite being immediate-release 1
• Diazepam is rapidly redistributed and seizures often recur within 15-20 minutes, requiring immediate follow-up with long-acting anticonvulsants 1

Evidence-Based Comparison

Lorazepam is generally preferred over diazepam for initial IV treatment of status epilepticus 1:

• In pediatric guidelines, lorazepam is noted as potentially preferred because it has a prolonged duration of anticonvulsant activity compared to diazepam 1
• Meta-analyses show lorazepam superior to diazepam for seizure cessation (RR 0.64,95% CI 0.45-0.90) and lower risk of requiring additional drugs or general anesthesia (RR 0.63,95% CI 0.45-0.88) 2, 3
• However, other systematic reviews found no statistically significant differences between the two agents 4, 5

Clinical Algorithm for Benzodiazepine Selection

For status epilepticus requiring immediate intervention:

1. First-line benzodiazepine options (all immediate-release):

   • IV lorazepam 0.1 mg/kg (maximum 4 mg per dose) 6
   • IV diazepam 0.15-0.3 mg/kg 1
   • IM midazolam (if IV access unavailable)

2. Repeat dosing if seizures continue:

   • Second dose at 5 minutes if no response 7
   • Maximum total lorazepam: typically 8 mg 6

3. If benzodiazepines fail:

   • Proceed immediately to second-line agents (fosphenytoin, levetiracetam, or valproate) 8

Common Pitfalls

• Underdosing is widespread: Only 17% of patients receive adequate initial benzodiazepine doses in real-world practice 9
• Don't confuse duration of action with extended-release: Lorazepam's longer anticonvulsant effect is due to pharmacokinetics, not a special formulation
• Diazepam requires immediate follow-up: Must be followed by long-acting anticonvulsants due to rapid redistribution 1
• Respiratory depression risk: Both agents carry similar risks when combined with other sedatives; be prepared to support ventilation 1